- Home
- APVO vs CMBM Comparison
APVO vs CMBM Comparison
Compare APVO & CMBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- CMBM
- Stock Information
- Founded
- APVO 2016
- CMBM 2011
- Country
- APVO United States
- CMBM United States
- Employees
- APVO N/A
- CMBM N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- CMBM Radio And Television Broadcasting And Communications Equipment
- Sector
- APVO Health Care
- CMBM Technology
- Exchange
- APVO Nasdaq
- CMBM Nasdaq
- Market Cap
- APVO 21.7M
- CMBM 17.7M
- IPO Year
- APVO N/A
- CMBM 2019
- Fundamental
- Price
- APVO $1.09
- CMBM $2.47
- Analyst Decision
- APVO
- CMBM
- Analyst Count
- APVO 0
- CMBM 0
- Target Price
- APVO N/A
- CMBM N/A
- AVG Volume (30 Days)
- APVO 757.7K
- CMBM 49.6M
- Earning Date
- APVO 11-06-2025
- CMBM 11-06-2025
- Dividend Yield
- APVO N/A
- CMBM N/A
- EPS Growth
- APVO N/A
- CMBM N/A
- EPS
- APVO N/A
- CMBM N/A
- Revenue
- APVO N/A
- CMBM $172,215,000.00
- Revenue This Year
- APVO N/A
- CMBM N/A
- Revenue Next Year
- APVO N/A
- CMBM $18.01
- P/E Ratio
- APVO N/A
- CMBM N/A
- Revenue Growth
- APVO N/A
- CMBM N/A
- 52 Week Low
- APVO $1.07
- CMBM $0.23
- 52 Week High
- APVO $298.00
- CMBM $6.80
- Technical
- Relative Strength Index (RSI)
- APVO 27.92
- CMBM 53.99
- Support Level
- APVO $1.39
- CMBM $2.44
- Resistance Level
- APVO $1.54
- CMBM $2.97
- Average True Range (ATR)
- APVO 0.09
- CMBM 0.67
- MACD
- APVO -0.03
- CMBM -0.06
- Stochastic Oscillator
- APVO 3.06
- CMBM 23.13
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.